The U.S.
Food and Drug Administration on Tuesday granted modified risk tobacco product (MRTP) orders to Philip Morris International Inc.'s (NYSE:PM) subsidiary for 20 ZYN nicotine pouch products.
The update allows the company to market them with claims that switching completely from cigarettes to the products lowers the risk of several smoking-related diseases.
The decision follows an extensive scientific review and applies only to the authorized ZYN products, not to nicotine pouches as a broader category.
Read Also: Philip Morris' Expansion Plans For Smoke-Free Products Hits Roadblock As India Upholds E-Cigarette Ban FDA Authorizes Reduced Risk Marketing Claim The FDA said the authorized ZYN nicotine pouches, which have been approved for sale in the U.S. since January 2025, may now carry the claim: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." The modified risk orders cover 10 ZYN varieties—Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen—each available in 3 milligram and 6 milligram nicotine strengths.
